<DOC>
	<DOCNO>NCT01476787</DOCNO>
	<brief_summary>The purpose study evaluate effect combine treatment lenalidomide rituximab control Follicular Lymphoma disease also increase length response compare available standard combination chemotherapy treatment Follicular Lymphoma .</brief_summary>
	<brief_title>Combined Rituximab Lenalidomide Treatment Untreated Patients With Follicular Lymphoma</brief_title>
	<detailed_description>Follicular Lymphoma ( FL ) cancer B lymphocyte , type white blood cell . FL typically slowly progress incurable disease . Follicular lymphoma cell produce specific defect patient 's immune system impair ability control cancer . Lenalidomide show reverse specific immune defect cause FL patient . By include lenalidomide , RELEVANCE study aim eliminate cancer restore patient 's immune competence . The 'Relevance ' cooperative group trial conduct two companion study : RV-FOL-GELARC-0683 ( N=750 ) RV-FOL-GELARC-0683C ( N=250 ) ; combine total 1000 Follicular Lymphoma patient enrol study analyze .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm follicular lymphoma grade 1 , 2 3a , Stage IIIV Have prior systemic treatment lymphoma Symptomatic follicular lymphoma require treatment . Age ≥18 year Eastern Cooperative oncology group performance status 02 Willing follow pregnancy precaution Clinical evidence transform lymphoma Grade 3b follicular lymphoma . Major surgery ( exclude lymph node biopsy ) within 28 day prior sign inform consent . Known seropositive active viral infection hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Known sensitivity allergy murine product . Presence history central nervous system involvement lymphoma At high risk venous thromboembolic event ( VTE ) willing take VTE prophylaxis Any follow laboratory abnormality : serum aspartate transaminase alanine transaminase &gt; 3x upper limit normal ( ULN ) , except patient document liver involvement lymphoma total bilirubin &gt; 2.0 mg/dl ( 34 µmol/L ) except case Gilberts Syndrome document liver pancreatic involvement lymphoma creatinine clearance &lt; 30 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Follicular lymphoma</keyword>
	<keyword>Non-Hodgkins Follicular Lymphoma</keyword>
	<keyword>treatment Follicular Lymphoma</keyword>
	<keyword>rituximab treatment</keyword>
	<keyword>rituximab lenalidomide treatment</keyword>
</DOC>